 Triazoles are a class of compounds that have shown promising antimicrobial activity against various pathogens including fungi, bacteria, and viruses. They have been used in the treatment of several infectious diseases, including candidiasis, cryptococcal meningitis, and aspergillosis. Despite advances in antifungal therapies, mortality from these infections remains unacceptably high. New antifungal agents targeting specific fungal structures or functions are being developed to address this need. Recent advancements in molecular mycology have enabled researchers to identify novel targets for antifungal drugs, leading to a greater understanding of how these compounds work and how they can be improved upon. This has resulted in a greater number of effective antifungal agents available for treating systemic fungal diseases. This article was authored by Kumari Shalini, Niden Kumar, Sushma Drabu, and others.